While EEG data can be applied in many clinical settings, Dr. Freeman emphasized the value of QEEG biomarkers in the study of a number of specialty patient populations, including those who suffer from depression, Alzheimer's disease, and other psychiatric disorders. He also offered a model for the development of an "EEG Warehouse" that would function in much the same way as the FDA's ECG warehouse to standardize and centrally store EEG data collected in clinical trials.
According to Dr. Gary Zammit, President & CEO of Clinilabs, "diagnostics are a central focus of clinical research, and the use of biomarkers to classify patients is of increasing interest in specialty clinical trials and the field of personalized medicine". Zammit also notes that the creation of an EEG warehouse represents "a wonderful opportunity for government, academia, and industry to work together to centralize data that can support the use of EEG as an outcome measure, a safety measure, or a biological marker in clinical trials.
About Clinilabs Inc.
Clinilabs is a contract research organization (CRO) that provides early-phase and specialty clinical drug development services to industry. We offer teams, processes, and technology solutions that are designed to serve single center and multicenter early-phase studies – services that can be scaled as needed to meet the requirements of any clinical development program. For more information, please visit www.clinilabs.com.
For more information or to schedule an interview, please contact Jeanine Estrada at 646.450.2215 or e-mail jestrada@clinilabs.com.
